Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.

Meghan Markle's As Ever logo includes a tribute to Prince Harry. Inside the symbolism and what the Duchess of Sussex has said ...

GSK’s pentavalent option comes well after vaccine rival Pfizer and its Penbraya hit the market in 2023. That shot similarly mixes components from the company’s other meningococcal vaccines ...

combines the immune response-generating components of two of the company's approved vaccines, Bexsero and Menveo, to protect against the five most common strains of meningococcal bacteria, GSK ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

It also gives breathing room for the company ... GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations ...

GSK declined comment, saying, “It is our consistent position that we do not comment on individual shareholders." A short position represents a bet that a company's stock will fall in value.

GSK, with its diversified portfolio, therefore reaches more physicians than any other company in the market. "GSK maintains a relatively large field force, reaching the majority of physicians in a ...

The company, based in Dundee, Scotland, says it has already produced drug candidates for other clients in one quarter of the time normally needed. Exscientia and GSK aim to discover novel and ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...